.jpg?format=webp&quality=80&width=3840)
The study compared the outcomes of single-fraction high-dose-rate (HDR) brachytherapy and single-fraction low-dose-rate (LDR) brachytherapy as the only treatment for primary prostate cancer in low and intermediate-risk patients. The results showed that LDR had significantly better biochemical relapse-free survival and overall survival rates compared to HDR. The study concluded that permanent LDR prostate implant brachytherapy is a better treatment option for primary prostate cancer.
Like
Save
Share